When we get older, our blood and immune systems become weaker. This happens because the special cells in bone marrow called hematopoietic stem cells (HSCs) stop working as well. Healthy HSCs can make many kinds of blood cells and keep renewing themselves. As we age, they make fewer new cells, favor some types over others, and cannot support a strong immune response.
Scientists think several things cause this slowdown: damage that builds up inside cells, changes in gene activity, low‑grade inflammation, and a shifting environment in the bone marrow. How all these stresses work together was still unclear.
Looking at a Key Aging Pathway
Researchers from the University of Tokyo and St. Jude Children’s Research Hospital studied how age‑related stress affects HSCs. They focused on a signaling pair called RIPK3‑MLKL, which is usually linked to a type of programmed cell death called necroptosis.
A Surprising Clue About MLKL
In mice that lack the MLKL protein, the scientists noticed something odd. Even after repeated chemotherapy‑like treatment, the mice’s HSCs showed far fewer aging‑related problems, even though the number of dead HSCs did not change. This made them wonder if MLKL could affect aging without actually killing the cells.
How the Experiments Were Done
The team used normal mice, mice without MLKL, and mice without RIPK3. They also created reporter mice that glow when MLKL becomes active. The animals were exposed to stress that mimics aging, such as inflammation and DNA‑replication stress. The main test was a bone‑marrow transplant, which shows how well HSCs can rebuild the blood system.
They added many other tools: flow cytometry, RNA sequencing, chromatin accessibility tests, high‑resolution pictures, metabolic measurements, and detailed studies of mitochondria. All of these helped see exactly how MLKL changes HSCs.
MLKL Hurts Mitochondria, Not Cells
Usually, MLKL triggers cell death. Here, the scientists found that when MLKL is turned on in stressed HSCs, it briefly moves to the mitochondria—the cell’s power plants. Inside the mitochondria, MLKL lowers the membrane potential, reshapes the organelle, and cuts energy production. These changes cause classic signs of aging: the stem cells cannot renew themselves well, they make fewer lymphoid cells, and they start producing more myeloid cells.
Stopping MLKL Saves Stem Cells
When MLKL was removed or blocked, many aging problems went away. The HSCs kept their ability to regenerate, created healthier immune cells, showed less DNA damage, and kept their mitochondria working better. This happened even in older mice or under stressful conditions.
Interestingly, these improvements did not depend on big changes in gene activity or DNA packaging. Instead, MLKL seems to act after genes are turned on, directly damaging mitochondria.
What This Means for the Future
These results point to a common route that links many kinds of cellular stress to mitochondrial damage and stem‑cell aging. By spotting MLKL as a key link, the study opens new ideas for medicines that protect mitochondria or adjust necroptosis pathways.
In the long run, such therapies could keep HSCs healthy, helping patients recover faster after chemotherapy, radiation, or bone‑marrow transplants. Understanding that a “death” protein can age stem cells without killing them may lead to new drugs that slow down age‑related decline in the blood and immune system.